OBJECTIVE: Postmenopausal hormone use and risk of breast cancer by histopathology was examined in a large multi-centered population-based case-control study. METHODS: Women younger than 75 years newly diagnosed with invasive breast cancer between 1988 and 1991 were identified from statewide tumour registries in Wisconsin, Massachusetts, New Hampshire, and Maine. Only postmenopausal women were included in this analysis. Breast cancer cases (lobular (n = 219), ductal, NOS (n = 2172), and specific ductal subtypes (n = 242)) were compared with randomly selected population controls (n = 3179) using adjusted multi-variable polytomous logistic regression to estimate odds ratios (OR) and 95% confidence intervals (95%CI) for each histology. RESULTS: Lobular carcinoma was associated with recent (within 2 years) estrogen therapy (OR: 1.8, 95% CI: 1.0-3.4) and recent use of combined estrogen-plus-progestin therapy (OR:3.6, 95%CI: 1.8-7.6). Risk of ductal carcinoma was not associated with recent use of either estrogen alone (OR: 0.9, 95% CI: 0.7-1.2) or combined therapy (OR:0.9, 95% CI: 0.6-1.3). No associations were found with ductal subtypes. CONCLUSIONS: The association between postmenopausal hormone use and risk of breast cancer may depend on histopathology. Of particular interest is the association between combined hormone therapy and increased risk of lobular carcinoma. This lesion is increasingly common but, nonetheless, comprises fewer than 10% of invasive breast cancers.
OBJECTIVE: Postmenopausal hormone use and risk of breast cancer by histopathology was examined in a large multi-centered population-based case-control study. METHODS:Women younger than 75 years newly diagnosed with invasive breast cancer between 1988 and 1991 were identified from statewide tumour registries in Wisconsin, Massachusetts, New Hampshire, and Maine. Only postmenopausal women were included in this analysis. Breast cancer cases (lobular (n = 219), ductal, NOS (n = 2172), and specific ductal subtypes (n = 242)) were compared with randomly selected population controls (n = 3179) using adjusted multi-variable polytomous logistic regression to estimate odds ratios (OR) and 95% confidence intervals (95%CI) for each histology. RESULTS:Lobular carcinoma was associated with recent (within 2 years) estrogen therapy (OR: 1.8, 95% CI: 1.0-3.4) and recent use of combined estrogen-plus-progestin therapy (OR:3.6, 95%CI: 1.8-7.6). Risk of ductal carcinoma was not associated with recent use of either estrogen alone (OR: 0.9, 95% CI: 0.7-1.2) or combined therapy (OR:0.9, 95% CI: 0.6-1.3). No associations were found with ductal subtypes. CONCLUSIONS: The association between postmenopausal hormone use and risk of breast cancer may depend on histopathology. Of particular interest is the association between combined hormone therapy and increased risk of lobular carcinoma. This lesion is increasingly common but, nonetheless, comprises fewer than 10% of invasive breast cancers.
Authors: Kerryn W Reding; Christopher I Li; Noel S Weiss; Chu Chen; Christopher S Carlson; David Duggan; Kenneth E Thummel; Janet R Daling; Kathleen E Malone Journal: Am J Epidemiol Date: 2009-10-21 Impact factor: 4.897
Authors: Mary Panjari; Robin Bell; Marijana Lijovic; Maria La China; Max Schwarz; Pamela Fradkin; Jo Bradbury; Helen Farrugia; Susan R Davis Journal: Horm Cancer Date: 2010-03-09 Impact factor: 3.869
Authors: S Warren Andersen; P A Newcomb; J M Hampton; L Titus-Ernstoff; K M Egan; A Trentham-Dietz Journal: Breast Cancer Res Treat Date: 2011-07-19 Impact factor: 4.872
Authors: Christopher I Li; Rowan T Chlebowski; Matthew Freiberg; Karen C Johnson; Lewis Kuller; Dorothy Lane; Lawrence Lessin; Mary Jo O'Sullivan; Jean Wactawski-Wende; Shagufta Yasmeen; Ross Prentice Journal: J Natl Cancer Inst Date: 2010-08-23 Impact factor: 13.506
Authors: Polly A Newcomb; Amy Trentham-Dietz; John M Hampton; Kathleen M Egan; Linda Titus-Ernstoff; Shaneda Warren Andersen; E Robert Greenberg; Walter C Willett Journal: Cancer Date: 2010-11-10 Impact factor: 6.860
Authors: Meghan E Work; Irene L Andrulis; Esther M John; John L Hopper; Yuyan Liao; Fang Fang Zhang; Julia A Knight; Dee W West; Roger L Milne; Graham G Giles; Teri A Longacre; Frances O'Malley; Anna Marie Mulligan; Melissa C Southey; Hanina Hibshoosh; Mary Beth Terry Journal: Breast Cancer Res Treat Date: 2012-04-25 Impact factor: 4.872
Authors: Louise A Brinton; Douglas Richesson; Michael F Leitzmann; Gretchen L Gierach; Arthur Schatzkin; Traci Mouw; Albert R Hollenbeck; James V Lacey Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254
Authors: Christopher I Li; Janet R Daling; Kara L Haugen; Mei Tzu Chen Tang; Peggy L Porter; Kathleen E Malone Journal: Breast Cancer Res Treat Date: 2014-04-20 Impact factor: 4.872